Background This study aimed to assess the serial changes in de novo coronary lesions,
including acute coronary syndrome (ACS), treated with a drug-coated balloon (DCB) …

Background Drug-coated balloon (DCB) treatment for de novo coronary artery disease has
demonstrated late lumen enlargement (LLE) in mid-term follow-up and it was considered as …

Purpose Data are limited on the long-term efficacy and safety of drug-coated balloon (DCB)
treatment in comparison to drug-eluting stent (DES) for de novo coronary lesions. We …

Background Percutaneous coronary intervention (PCI) is the main treatment option for acute
coronary syndromes (ACS) often related to the progression and rupture of vulnerable …

Aims To assess the serial changes of de novo coronary lesions treated with paclitaxel-
coated balloon (PCB) using intravascular ultrasound virtual histology (IVUS-VH) and …

Background: Since their emergence, drug-coated balloons (DCBs) have been used widely
to treat in-stent lesions with coronary artery disease (CAD). However, despite their superior …

This study aimed to assess the healing response, as evidenced through temporal
morphological and functional changes, following paclitaxel-coated balloon (PCB) treatment …

Background Drug-coated balloons (DCB), alone or in combination with drug-eluting stents
(DES), may be used to treat diffuse coronary lesions. We aimed to explore the efficacy and …

Although drug-eluting stents (DES) have become the mainstay of percutaneous coronary
intervention, late and very late stent thrombosis remains a concern. Drug-coated balloons …

Background Acute physiological changes after balloon angioplasty are very important
because of acute recoil and dissection. However, serial physiological assessments after …